Coya Therapeutics earnings release, August 11, 2026

Coya Therapeutics, Inc. (COYA) · Form 8-K, Item 2.02 · Filed · SEC filing

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

HOUSTON, TX., August 11, 2026 (BUSINESS WIRE)--

Coya Therapeutics, Inc.

(NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update.

“During the second quarter, we made notable progress advancing our lead program, COYA 302,” said Arun Swaminathan, Ph.D., Chief Executive Officer of Coya. “Enrollment in the ALSTARS Phase 2 ALS trial is proceeding as planned, and we remain on track to complete enrollment this year and report topline data in the first quarter of 2027. At the same time, we plan to initiate a Phase 2 study of COYA 302 in frontotemporal dementia (FTD) in the coming months. Together, these programs reflect our differentiated strategy of applying Treg biology to address the shared mechanisms of these neurodegenerative conditions.”

Recent Corporate Highlights

• Announced that the first cohort of patients has progressed into the 24-week blinded active treatment extension phase in the ALSTARS Phase 2 Trial.

• Received FDA Fast Track Designation for COYA 302 for the treatment of ALS. Fast Track Designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and address unmet medical needs.

• Appointed Mark H. Pavao as Independent Director.

• Announced a publication in the journal

Annals of Clinical and Translational Neurology demonstrating the correlation between longitudinal biomarker data and clinical outcomes supporting the mechanistic rationale for COYA 302 in patients with ALS.

• Delivered scientific presentations on the ALSTARS Phase 2 clinical trial design at the 5 th

Annual ALS Drug Development Summit and ENCALS (European Network to Cure ALS) Meeting 2026.

• Hosted a virtual webinar titled, ‘

Beyond the Hit: How Repetitive Head Trauma, Inflammation, and Neurodegenerative Disease Intersect’, which explored the relationship between repetitive head trauma, brain inflammation and neurodegenerative diseases with leading experts in the field.

Upcoming Expected Milestones 2026:

• 2H 2026: Complete enrollment in the ALSTARS Phase 2 trial.

• 2H 2026: Initiate a Phase 2 study evaluating COYA 302 for the treatment of FTD.

• 2H 2026: Announce biomarker data from the completed investigator-initiated study in patients with FTD

• 2H 2026: Report additional single-cell proteomics data from the completed ALS and AD investigator-initiated trials.

• 2H 2026: Publish in vivo data on COYA 303 in an inflammatory animal model of peripheral and CNS inflammation.

“The progress we have made in the ALSTARS trial continues to reinforce our confidence in COYA 302 as we advance this program for people living with ALS,” said Fred Grossman, DO, FAPA, President and Chief Medical Officer of Coya. “The blinded extension phase of the ALSTARS trial is now well underway. We are grateful to the patients, families, and investigators whose partnership makes this work possible.”

Financial Results

As of June 30, 2026, Coya had cash and cash equivalents of $43.2 million, sufficient to fund operations, as currently planned, past the Phase 2 ALSTARS topline data readout and into the second half of 2027.

Collaboration revenue was $0.2 million for each of the three months ended June 30, 2026 and 2025, and related to the Company’s R&D services performance obligation under the Development and License Agreement with DRL.

Research and development expenses increased by $1.3 million from $3.7 million for the three months ended June 30, 2025 to $5.0 million for the three months ended June 30, 2026. The increase was primarily due to a $1.1 million increase in preclinical and clinical product candidate costs, reflecting primarily the advancement of the COYA 302 ALS Phase 2 clinical trial. The increase was further driven by a $0.4 million increase in internal research and development expenses, partially offset by a $0.2 million decrease in sponsored research expense.

General and administrative expenses decreased by $0.6 million from $2.9 million for the three months ended June 30, 2025 compared to $2.3 million for the three months ended June 30, 2026. The decrease was primarily due to a $0.4 million decrease in professional services and a $0.2 million decrease in employee compensation, including lower stock-based compensation.

Net loss was $6.6 million for the three months ended June 30, 2026, compared to net loss of $6.1 million for the three months ended June 30, 2025.

About Coya Therapeutics, Inc.

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.

Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

For more information about Coya, please visit www.coyatherapeutics.com

About COYA 302... (truncated) proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig and is being developed for subcutaneous administration for the treatment of patients with ALS, FTD and other neurodegenerative diseases. These mechanisms may have additive or synergistic effects.

Coya is currently conducting the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (Identifier: NCT07161999).

COYA 302 is an investigational product not yet approved by the FDA or any other regulatory agency.

Financial statements

Income Statement

Three Months Ended June 30, — CONDENSED UNAUDITED INTERIM STATEMENTS OF OPERATIONS

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025
Collaboration revenue243,745163,616
Operating expenses:Research and development5,030,6673,663,103
Operating expenses:In-process research and development1,656
Operating expenses:General and administrative2,255,6032,908,191
Operating expenses:Depreciation2,8076,840
Operating expenses:Total operating expenses7,290,7336,578,134
Operating expenses:Loss from operations-7,046,988-6,414,518
Other income:Other income408,728319,541
Other income:Pre-tax loss-6,638,260-6,094,977
Other income:Net loss-6,638,260-6,094,977
Per share information:Net loss per share of common stock, basic and diluted-0.28-0.36
Per share information:Weighted-average shares of common stock outstanding, basic and diluted23,457,22716,724,998

Balance Sheet

CONDENSED BALANCE SHEETS

(unaudited) – June 30, – 2026December 31, – 2025
Current assets:Cash and cash equivalents43,181,00246,822,786
Current assets:Prepaids and other current assets3,876,7353,116,232
Current assets:Total current assets47,057,73749,939,018
Current assets:Fixed assets, net5,61411,227
Current assets:Other assets244,727
Current assets:Total assets47,308,07849,950,245
Current liabilities:Accounts payable1,085,5191,061,122
Current liabilities:Accrued expenses1,193,4603,612,913
Current liabilities:Deferred collaboration revenue1,233,4521,197,856
Current liabilities:Total current liabilities3,512,4315,871,891
Current liabilities:Deferred collaboration revenue519,6361,050,124
Current liabilities:Total liabilities4,032,0676,922,015
Stockholders' equity:Common stock, $0.0001 par value; 200,000,000 shares authorized; 23,457,849 and 20,934,456 shares issued and outstanding as of June 30, 2026 or December 31, 2025, respectively2,3462,094
Stockholders' equity:Additional paid-in capital119,082,192104,989,413
Stockholders' equity:Accumulated deficit-75,808,527-61,963,277
Stockholders' equity:Total stockholders' equity43,276,01143,028,230
Stockholders' equity:Total liabilities and stockholders' equity47,308,07849,950,245

Cash Flow

Six Months Ended June 30, — CONDENSED UNAUDITED INTERIM STATEMENTS OF CASH FLOWS

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cash flows from operating activities:Net loss-13,845,250-13,401,734
Adjustment to reconcile net loss to net cash used in operating activities:Depreciation5,61413,680
Adjustment to reconcile net loss to net cash used in operating activities:Stock-based compensation, including the issuance of restricted stock3,139,4272,115,795
Adjustment to reconcile net loss to net cash used in operating activities:Acquired in-process research and development assets11,656
Changes in operating assets and liabilities:Prepaids and other current assets-640,0622,298,347
Changes in operating assets and liabilities:Other assets-120,441
Changes in operating assets and liabilities:Accounts payable-96,044-656,784
Changes in operating assets and liabilities:Accrued expenses-1,544,4541,450,625
Changes in operating assets and liabilities:Deferred collaboration revenue-494,892-421,500
Changes in operating assets and liabilities:Net cash used in operating activities-13,584,446-8,601,571
Cash flows from investing activities:Purchase of in-process research and development assets-886,656
Cash flows from investing activities:Net cash used in investing activities-886,656
Cash flows from financing activities:Proceeds from sale of common stock, net of offering costs10,953,604
Cash flows from financing activities:Payment of financing costs related to the ATM Offering Program-124,286
Cash flows from financing activities:Proceeds from the exercise of stock options19,137
Cash flows from financing activities:Net cash provided by financing activities10,829,31819,137
Cash flows from financing activities:Net decrease in cash and cash equivalents-3,641,784-8,582,434
Cash flows from financing activities:Cash and cash equivalents as of beginning of the period46,822,78638,339,762
Cash flows from financing activities:Cash and cash equivalents as of end of the period43,181,00229,757,328
Supplemental disclosures of non-cash investing and financing activities:In-process research and development costs in accrued expenses250,000$-
Supplemental disclosures of non-cash investing and financing activities:Financing costs related to the ATM Offering Program in accounts payable120,441$-
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Coya

Therapeutics, Inc. (the “Company”) regarding the potential benefits, effectiveness and safety of its product candidates; the significance and potential benefits associated with the FDA’s Fast Track designation for COYA 302; the Company’s ability to advance its product candidates through the preclinical and clinical development processes; the Company’s expectations regarding, quality, timing and availability of data from the Company’s clinical trials; the timing of announcements, updates and results of the Company’s clinical trials and related data; the Company’s future results of operations and financial position, including cash runway; and the potential therapeutic benefits and economic value of the Company’s product candidates. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact

David Snyder, CFO david@coyatherapeutics.com

Media Contacts

Russo Partners

David Schull

David.Schull@russopartnersllc.com

858-717-2310

Rachelle Babb rachelle.babb@russopartnersllc.com

929-325-7559

Source: Coya Therapeutics, Inc.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Coya Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.